Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent Clostridioides difficile infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial. - Khanna S; Yoho D; Van Handel D; Clark BJ; Awad T; Guthmueller B; Armandi D; Knapple W; Safdar N; Baggott B; Simon K; Feuerstadt P (Therapeutic advances in gastroenterology, 2025)